13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest an oncolytic herpes simplex virus (HSV) expressing CDH1 could help treat glioblastoma multiforme (GBM). An oncolytic HSV was engineered to express human CDH1 to enhance cell-to-cell transmission and reduce...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
17:37 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to...
21:15 , Oct 22, 2018 |  BC Extra  |  Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to...
20:33 , Oct 5, 2018 |  BC Week In Review  |  Company News

Janssen terminates licenses to Aduro cancer therapies

Aduro BioTech Inc. (NASDAQ:ADRO) revealed in an SEC filing that the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) will terminate its licenses for three cancer therapies, effective Dec. 24. A Janssen spokesperson told...
20:05 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample, cell culture and mouse studies suggest inhibiting PCBP1 could help treat MS. In brain tissue samples from MS patients, PCBP1 expression was higher in MS lesions than in matched...
17:22 , Jul 27, 2018 |  BC Week In Review  |  Company News

Lee's mulls spin off, HK IPO for China oncology subsidiary

Lee's Pharmaceutical Holdings Ltd. (HKSE:950) said it will consolidate its oncology development pipeline into its China Oncology Focus Ltd. (COF) subsidiary. Lee's CFO Jason Chow told BioCentury that the company expects the reorganization to potentiate...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

GSK, 23andMe partner on target, drug discovery

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on July 25, when the pharma provided an R&D update, announced 2Q18...
23:14 , Jul 25, 2018 |  BC Extra  |  Company News

GSK's near-term R&D prospects include an ADC as it pivots to immunology

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on Wednesday, when the pharma provided an R&D update, announced 2Q18 earnings...
18:13 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Replimune prices $100.5M IPO in middle of range

Replimune Group Inc. (NASDAQ:REPL) raised $100.5 million late July 19 through the sale of 6.7 million shares at $15 in an IPO underwritten by J.P. Morgan, Leerink and BMO Capital Markets. The price, which was...